z-logo
open-access-imgOpen Access
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval
Author(s) -
Caitríona Goggin,
Anna Stansfeld,
Preethika Mahalingam,
Khin Thway,
Myles Smith,
Paul H. Huang,
Robin L. Jones,
Andrea Napolitano
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0226
Subject(s) - medicine , imatinib , tyrosine kinase inhibitor , gist , stromal cell , targeted therapy , oncology , imatinib mesylate , sunitinib , tyrosine kinase , drug resistance , disease , cancer research , cancer , receptor , myeloid leukemia , microbiology and biotechnology , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here